VEOPOZ

GrowthmAb

pozelimab

BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
18

Mechanism of Action

Complement Inhibitors

Pharmacologic Class:

Complement Inhibitor

Clinical Trials (5)

NCT07154745Phase 3Recruiting

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

Started Mar 2026
35 enrolled
Paroxysmal Nocturnal Hemoglobinuria
NCT07142343Phase 4Recruiting

A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease

Started Mar 2026
5 enrolled
CHAPLE Disease
NCT07230834Phase 1Recruiting

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Started Jan 2026
54 enrolled
Geographic Atrophy (GA)
NCT06541704Phase 3Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Started Oct 2024
975 enrolled
Age-related Macular Degeneration (AMD)Geographic Atrophy (GA)
NCT06479863Phase 1Recruiting

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

Started Aug 2024
10 enrolled
Sporadic Inclusion Body Myositis (sIBM)Idiopathic Inflammatory Myopathies